Full Press Release Details
Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results
SOUTH SAN FRANCISCO, Calif. - Aug. 15, 2022 - Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the "Company" or "we") today announced its operating and financial results for the second quarter ended June 30, 2022.
"We were very pleased to have completed the sale of our complement portfolio during the second quarter to Vertex Pharmaceuticals Incorporated
(NASDAQ: VRTX) ("Vertex") for $60.0 million in cash with up to $5.0 million of that amount due in May 2023. This transaction was the result of a comprehensive and competitive review of strategic alternatives led by the Company's Board of Directors
(the "Board"), management team and independent legal and financial advisors" said Nassim Usman, Ph.D., President and Chief Executive Officer of Catalyst.
Dr. Usman continued, "This quarter's results reflect our efforts to aggressively reduce costs through headcount reductions, ceasing all research
and development activities, terminating our lab lease and monetizing lab and other equipment. Our focus now is on distributing all of the Company's available cash expeditiously to stockholders, after paying or reserving for obligations and
liabilities. We look forward to making an initial distribution of $45.0 million as soon as practicable, pending resolution of the stockholder litigation. In the meantime, we will continue to pursue the monetization of the Company's remaining
assets, which we hope will generate additional value for our stockholders."
Second Quarter Milestones
Second Quarter 2022 Results and Financial Highlights
About Catalyst Biosciences
Catalyst is a biopharmaceutical company focused on protease therapeutics to address unmet medical needs in disorders of the complement and coagulation systems. After the transaction
of its complement pipeline, Catalyst's product candidates consist of the coagulation related assets marzeptacog alfa (activated) ("MarzAA"), dalcinonacog alfa ("DalcA"), and CB 2679d-GT. MarzAA is a SQ administered next generation engineered
coagulation Factor VIIa ("FVIIa") for the treatment of episodic bleeding and prophylaxis in subjects with rare bleeding disorders. DalcA is a next-generation SQ administered FIX. CB 2679d-GT is an AAV-based gene therapy construct harboring the
DalcA sequence. Both MarzAA and DalcA have shown sustained efficacy and safety in mid-stage clinical trials and are available for partnering. CB 2679d-GT has obtained preclinical proof-of-concept and is also available for partnering.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include, without limitation, those regarding the
amount and timing of planned cash distributions, potential uses of and markets for MarzAA, DalcA and CB 2679-GT, and Catalyst's plans to continue to explore strategic alternatives. Actual results or events could differ materially from the plans,
intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risks that Catalyst's obligations and
liabilities will be greater than anticipated, that the pending litigation with JDS1 will not be resolved in a timely manner and the expenses associated with that litigation will be greater than anticipated, that Catalyst will not be able to
identify strategic partners interested in MarzAA, DalcA, CB 2679-GT or any other transaction with the Company, and other risks described in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and
Exchange Commission (the "SEC") on March 31, 2022, the Quarterly Report on Form 10-Q filed with the SEC on August 15, 2022, and in other filings filed from time to time with the SEC. The Company does not assume any obligation to update any
forward-looking statements, except as required by law.
Catalyst Biosciences, Inc.
Catalyst Biosciences, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| June 30, 2022 | December 31, 2021 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 75,394 | $ | 44,347 | ||||
| Short-term investments | - | 2,504 | ||||||
| Accounts and other receivables, net | 5,000 | 1,818 | ||||||
| Prepaid and other current assets | 914 | 2,807 | ||||||
| Total current assets | 81,308 | 51,476 | ||||||
| Other assets, noncurrent | 168 | 472 | ||||||
| Right-of-use assets | 1,733 | 2,744 | ||||||
| Property and equipment, net | 164 | 970 | ||||||
| Total assets | $ | 83,373 | $ | 55,662 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,037 | $ | 6,419 | ||||
| Accrued compensation | 911 | 1,467 | ||||||
| Deferred revenue | - | 230 | ||||||
| Other accrued liabilities | 948 | 4,072 | ||||||
| Operating lease liability | 1,415 | 1,977 | ||||||
| Total current liabilities | 4,311 | 14,165 | ||||||
| Operating lease liability, noncurrent | - | 408 | ||||||
| Total liabilities | 4,311 | 14,573 | ||||||
| Stockholders' equity: | ||||||||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized; zero shares issued and outstanding | - | - | ||||||
| Common stock, $0.001 par value, 100,000,000 shares authorized; 31,477,053 and 31,409,707 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively | 31 | 31 | ||||||
| Additional paid-in capital | 444,629 | 443,752 | ||||||
| Accumulated deficit | (365,598 | ) | (402,694 | ) | ||||
| Total stockholders' equity | 79,062 | 41,089 | ||||||
| Total liabilities and stockholders' equity | $ | 83,373 | $ | 55,662 |
Catalyst Biosciences, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue: | ||||||||||||||||
| Collaboration | $ | - | $ | 1,132 | $ | 794 | $ | 2,599 | ||||||||
| Operating expenses (income): | ||||||||||||||||
| Cost of collaboration | - | 1,139 | 798 | 2,619 | ||||||||||||
| Research and development | 1,871 | 15,389 | 11,574 | 32,402 | ||||||||||||
| General and administrative | 3,844 | 4,518 | 8,838 | 9,930 | ||||||||||||
| Gain on disposal of assets, net | (57,245 | ) | - | (57,245 | ) | - | ||||||||||
| Total operating expenses (income) | (51,530 | ) | 21,046 | (36,035 | ) | 44,951 | ||||||||||
| Income (loss) from operations | 51,530 | (19,914 | ) | 36,829 | (42,352 | ) | ||||||||||
| Interest and other income (expense), net | 102 | (14 | ) | 267 | (14 | ) | ||||||||||
| Net income (loss) | $ | 51,632 | $ | (19,928 | ) | $ | 37,096 | $ | (42,366 | ) | ||||||
| Net income (loss) per share attributable to common stockholders, basic | $ | 1.64 | $ | (0.64 | ) | $ | 1.18 | $ | (1.42 | ) | ||||||
| Net income (loss) per share attributable to common stockholders, diluted | $ | 1.64 | $ | (0.64 | ) | $ | 1.18 | $ | (1.42 | ) | ||||||
| Shares used to compute net income (loss) per share attributable to common stockholders, basic | 31,477,053 | 31,348,602 | 31,466,630 | 29,875,202 | ||||||||||||
| Shares used to compute net income (loss) per share attributable to common stockholders, diluted | 31,482,925 | 31,348,602 | 31,469,566 | 29,875,202 |